Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease : An 8-Year Nationwide Cohort Study in Taiwan

doi:10.1097/MD.0000000000002113

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 生活保健科技系 > 期刊論文 > Item 310902800/29684

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/29684

標題:	Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease : An 8-Year Nationwide Cohort Study in Taiwan
作者:	Hsu, Yueh-Han Hung, Peir-Haur Muo, Chih-Hsin Tsai, Wen-Chen Hsu, Chih-Cheng Kao, Chia-Hung
貢獻者:	生活應用與保健系
關鍵字:	population-basedcohort hemodialysis-patients antiviraltreatment kidney-disease increasedrisk hcvinfection association dialysis outcomes metaanalysis
日期:	2015-11
上傳時間:	2016-04-19 19:04:31 (UTC+8)
出版者:	Lippincott Williams & Wilkins
摘要:	The long-term survival of end-stage renal disease (ESRD) patients with hepatitis C virus (HCV) infection who received interferon treatment has not been extensively evaluated.The HCV cohort was the ESRD patients with de novo HCV infection from 2004 to 2011; they were classified into treated and untreated groups according to interferon therapy records. Patients aged <20 years and those with a history of hepatitis B, kidney transplantation, or cancer were excluded. The control cohort included ESRD patients without HCV infection matched 4:1 to the HCV cohort by age, sex, and year of ESRD registration. We followed up all study participants until kidney transplantation, death, or the end of 2011, whichever came first. We assessed risk of all-cause mortality by using the multivariate Cox proportional hazard model with time-dependent covariate.In the HCV cohort, 134 patients (6.01%) received interferon treatment. Compared with the uninfected control cohort, the treated group had a lower risk of death (hazard ratio 0.47, 95% confidence interval [CI] 0.22-0.99). The untreated group had a 2.62-fold higher risk (95% CI 1.24-5.55) of death compared with the treated group. For the HCV cohort without cirrhosis or hepatoma, the risk of death in the treated group was further markedly reduced (hazard ratio 0.17, 95% CI 0.04-0.68) compared with that in the control cohort.For ESRD patients with HCV infection, receiving interferon treatment is associated with a survival advantage. Such an advantage is more prominent in HCV patients without cirrhosis or hepatoma.
關聯:	Medicine, v.94 n.47, Article ID e2113
顯示於類別:	[生活保健科技系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
29684.pdf		281Kb	Adobe PDF	445	檢視/開啟
index.html		0Kb	HTML	1886	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....